Employee Stock Option Exercise at Sai Life Sciences

On April 23, 2026, Sai Life Sciences completed the issuance of 244,281 equity shares stemming from its ESOP 2008 and MESOP 2018 plans, collectively raising ₹3.38 crore. This move increases the company's total outstanding shares and results in equity dilution for existing shareholders.

Allotment Details

The shares were issued under the company's ESOP 2008 and MESOP 2018 plans. Employees exercised options at prices of ₹188.90 for ESOP 2008 shares and ₹127.30 for MESOP 2018 shares. Following this, the company's total issued share capital increased to 21,20,23,515 shares, with a total issued share capital value of ₹21.20 crore.

Shareholder Impact

This allotment directly increases the total number of outstanding shares. For existing shareholders, this means a marginal dilution in their percentage ownership. It also affects per-share metrics like Earnings Per Share (EPS), which could decrease if company profits remain steady.

Company Background and IPO Plans

Sai Life Sciences is a contract research, development, and manufacturing organization (CRDMO) serving the drug discovery value chain globally. The company, backed by private equity, is preparing for a public listing and has filed for an IPO.

History of Option Grants

Employee stock options are a key tool for talent retention in competitive sectors. Sai Life Sciences has previously granted options; in February 2026, it adjusted an allotment to 139,007 shares, and in April 2025, it allotted 46,510 shares under its ESOP schemes.

Key Risk

A primary risk from such issuances is the potential dilution of Earnings Per Share (EPS) for existing shareholders, stemming from the increased number of outstanding shares.

Peer Landscape

Sai Life Sciences operates in the CRDMO sector alongside companies like Syngene International, Gland Pharma, Divi's Laboratories, and Laurus Labs. While these peers may also use employee stock option plans, the immediate impact of this specific allotment is internal to Sai Life Sciences.

Investor Focus

Investors will monitor the company's future financial reports for the impact of the increased share count on EPS. They will also track the company's progress toward its IPO and its ongoing employee retention strategies.